#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16560	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2174	756.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1688	1688	T	889	T,C	834,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16560	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2174	756.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1422	1422	C	1032	C,A	968,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30416	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3702	819.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1740	1740	A	983	A,G	926,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30416	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3702	819.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2374	2374	C	972	C,T,A	915,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30416	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3702	819.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2448	2448	A	990	A	935	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	30416	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3702	819.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3000	3000	C	949	C,G	902,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	539	40006	blaTEM	861	861	99.88	blaTEM.l15.c4.ctg.1	1638	2433.6	0	.	p	.	0	M180T	NONSYN	538	540	ATG	885	887	ACG	3812;3805;3792	A,G;C,A;G,A,T	3567,1;3590,1;3563,2,1	.	Betalactam resistance
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2480	folP	855	855	100.0	folP.l15.c17.ctg.1	1665	148.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1131	1133	AGC	263;263;262	A;G;C	253;252;252	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6200	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3374	183.2	1	SNP	p	S91F	1	.	.	271	273	TTC	576	578	TTC	213;213;212	T;T;C	196;196;196	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6200	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3374	183.2	1	SNP	p	D95G	1	.	.	283	285	GGC	588	590	GGC	198;200;203	G;G;C,A	186;189;189,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	6200	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3374	183.2	1	SNP	p	G95N	0	.	.	283	285	GGC	588	590	GGC	198;200;203	G;G;C,A	186;189;189,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	2016	mtrR	633	633	99.68	mtrR.l6.c30.ctg.1	1425	140.8	0	.	p	.	0	D79N	NONSYN	235	237	GAT	680	682	AAT	245;246;246	A;A;T,G	232;232;230,1	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	2016	mtrR	633	633	99.68	mtrR.l6.c30.ctg.1	1425	140.8	0	.	p	.	0	S179fs	FSHIFT	535	535	T	981	981	C	235	C	222	.	.
mtrR.WHO_F_01564	mtrR.WHO_F_01564	1	1	539	2016	mtrR	633	633	99.68	mtrR.l6.c30.ctg.1	1425	140.8	1	SNP	p	G45D	0	.	.	133	135	GGC	578	580	GGC	245;244;240	G;G;C	235;232;230	mtrR.WHO_F_01564:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1082	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1000	107.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5810	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2900	199.5	1	SNP	p	D86N	1	D86N	NONSYN	256	258	GAC	595	597	AAC	233;230;233	A;A;C	220;217;220	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5810	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2900	199.5	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1642	1644	GCA	220;220;220	G;C;A	204;195;204	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5810	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2900	199.5	1	SNP	p	S87W	0	.	.	259	261	AGT	598	600	AGT	235;234;232	A;G;T,C	220;220;213,1	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5810	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2900	199.5	1	SNP	p	S87I	0	.	.	259	261	AGT	598	600	AGT	235;234;232	A;G;T,C	220;220;213,1	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5810	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2900	199.5	1	SNP	p	S87R	0	.	.	259	261	AGT	598	600	AGT	235;234;232	A;G;T,C	220;220;213,1	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5810	parC	2304	2304	99.74	parC.l15.c4.ctg.1	2900	199.5	1	SNP	p	S88P	0	.	.	262	264	TCC	601	603	TCC	235;232;234	T;C;C	218;217;219	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5290	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2708	194.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1576	1578	GGC	228;225;225	G;G;C	218;212;211	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.002	penA.2.002	1	1	27	4622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2465	186.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1260	1262	GCA	224;228;230	G;C;A	208;215;218	penA.2.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2465	186.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1263	1265	ATC	228;225;226	A;T;C	216;213;211	penA.2.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2465	186.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1275	1277	GTG	235;235;234	G;T;G	221;219;217	penA.2.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2465	186.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1275	1277	GTG	235;235;234	G;T;G	221;219;217	penA.2.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2465	186.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1779	1781	ACC	240;241;241	A,G;C;C	216,1;222;220	penA.2.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2465	186.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1833	1835	GCG	224;224;223	G;C;G	202;181;192	penA.2.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2465	186.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1833	1835	GCG	224;224;223	G;C;G	202;181;192	penA.2.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2465	186.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1956	1958	GGC	187;189;190	G;G;C	173;175;175	penA.2.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2465	186.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1965	1967	GGC	186;184;183	G;G;C	171;167;167	penA.2.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	4622	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2465	186.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1983	1985	CCG	162;170;167	C,G;C,G;G	120,8;127,1;121	penA.2.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	6646	ponA	2397	2397	99.87	ponA.l15.c17.ctg.1	2981	221.9	0	.	p	.	0	A375T	NONSYN	1123	1125	GCG	1416	1418	ACG	268;266;263	A,G;C;G	245,1;248;245	.	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	6646	ponA	2397	2397	99.87	ponA.l15.c17.ctg.1	2981	221.9	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1554	1556	CTG	257;259;259	C;T;G	227;233;236	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2678	porA	1146	1146	99.74	porA.l15.c4.ctg.1	1766	150.7	0	.	p	.	0	S22G	NONSYN	64	66	AGC	303	305	GGC	176;173;175	G;G;C	166;163;165	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2678	porA	1146	1146	99.74	porA.l15.c4.ctg.1	1766	150.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	485	485	C	192	C	179	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3202	porB1b	1047	1047	98.76	porB1b.l15.c17.ctg.1	1413	224.0	0	.	p	.	0	T26A	NONSYN	76	78	ACC	297	299	GCC	304;303;305	G;C,T;C	281;279,1;284	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3202	porB1b	1047	1047	98.76	porB1b.l15.c17.ctg.1	1413	224.0	0	.	p	.	0	N38E	NONSYN	112	114	AAT	333	335	GAA	269;268;267	G;A;A	256;257;254	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3202	porB1b	1047	1047	98.76	porB1b.l15.c17.ctg.1	1413	224.0	0	.	p	.	0	K41D	NONSYN	121	123	AAA	342	344	GAC	264;264;266	G;A;C	249;249;252	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3202	porB1b	1047	1047	98.76	porB1b.l15.c17.ctg.1	1413	224.0	0	.	p	.	0	N134D	NONSYN	400	402	AAT	621	623	GAT	269;273;273	G;A;T	252;254;256	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3202	porB1b	1047	1047	98.76	porB1b.l15.c17.ctg.1	1413	224.0	0	.	p	.	0	P175S	NONSYN	523	525	CCA	744	746	TCA	235;240;239	T;C;A	219;223;221	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3202	porB1b	1047	1047	98.76	porB1b.l15.c17.ctg.1	1413	224.0	0	.	p	.	0	G203S	NONSYN	607	609	GGC	828	830	AGC	251;249;249	A;G;C	239;233;235	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3202	porB1b	1047	1047	98.76	porB1b.l15.c17.ctg.1	1413	224.0	0	.	p	.	0	A218V	NONSYN	652	654	GCC	873	875	GTC	251;252;254	G;T;C	244;246;245	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3202	porB1b	1047	1047	98.76	porB1b.l15.c17.ctg.1	1413	224.0	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1203	1205	GCA	228;231;239	G;C;A	218;219;226	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3202	porB1b	1047	1047	98.76	porB1b.l15.c17.ctg.1	1413	224.0	1	SNP	p	G120K	1	.	.	358	360	AAG	579	581	AAG	234;237;238	A;A;G	224;226;226	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3202	porB1b	1047	1047	98.76	porB1b.l15.c17.ctg.1	1413	224.0	1	SNP	p	A121D	1	.	.	361	363	GAC	582	584	GAC	235;236;239	G;A;C	221;224;223	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3202	porB1b	1047	1047	98.76	porB1b.l15.c17.ctg.1	1413	224.0	1	SNP	p	D121N	0	.	.	361	363	GAC	582	584	GAC	235;236;239	G;A;C	221;224;223	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11808	rpoB	4179	4179	99.95	rpoB.l15.c4.ctg.1	4923	239.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1947	1949	AAT	236;237;241	A;A;T,A	228;229;232,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1372	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1216	112.5	1	SNP	p	V57M	1	.	.	169	171	ATG	582	584	ATG	270;271;277	A;T;G	254;256;261	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
tetM.WHO_G_pTetM_00047	tetM.WHO_G_pTetM_00047	1	0	27	12492	tetM	1920	1920	100.0	tetM.l15.c30.ctg.1	2726	457.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Tetracycline resistance
